In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the value of standardizing measurable residual disease (MRD) assessment in multiple myeloma, highlighting results from an imaging sub-study of the FORTE trial (NCT02203643). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.